Fungal infections 2

Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer

A L Colombo, J N de Almeida Júnior, Monica A Slavin, Sharon C-A Chen, Tania C Sorrell

Critically ill patients and patients with haematological cancer are HIV-negative populations at high risk of invasive fungal infections. In intensive-care units, candidaemia and intra-abdominal candidiasis predominate, but aspergillosis has emerged as a lethal, under-recognised cause of pneumonia. In patients with haematological malignancies or who have undergone stem-cell transplantations, pulmonary disease due to aspergillus and other mould diseases predominate. In this Series paper, we provide an update on risk assessment, new diagnostic strategies, and therapeutic approaches. New concepts have emerged for use of risk prediction rules and an evidence base now exists for inclusion of biomarkers (eg, galactomannan, 1,3-β-D-glucan, and PCR assays for Aspergillus spp) into early diagnostic and therapeutic strategies. Imaging techniques remain helpful for early diagnosis of pulmonary mould diseases, with PET techniques offering potential improvements in diagnostic specificity and evaluation of clinical response. Echinocandins and triazoles have been validated extensively for prophylaxis, empirical therapy, and targeted therapy, but an increase in intrinsically resistant fungi and emergence of secondary resistance as a result of drug-induced selection pressure are of major concern. Echinocandins remain a major component of treatment of invasive candidiasis and new triazoles are the best alternative for prophylaxis and therapy of invasive aspergillosis.

Introduction

Despite their differences in terms of medical scenarios, critically ill patients and patients with haematological cancer are two major groups at risk for developing invasive candida and aspergillus infections.1,2 In patients who are critically ill, candidaemia and intra-abdominal candidiasis are two major concerns in terms of morbidity and mortality due to fungal infections, but aspergillosis has emerged in several medical centres as one of the most lethal and under-recognised causes of fungal pneumonia.3 In haematological malignancies and stem cell transplant recipients, because of the widespread use of prophylaxis against candida infections, aspergillus and other moulds have emerged as the most common group of fungal infections causing morbidity and mortality.

Over the past 2 decades, a large number of newer diagnostic and therapeutic tools have been developed for the clinical management of fungal infections.4–6 At present, there are three echinocandins and three new triazoles that have been extensively validated in different regimens of prophylaxis, empirical, and targeted therapy. Unfortunately, most clinicians are still not familiar with the pros and cons of new diagnostic tests and there is strong evidence suggesting that up to 40–70% of antifungal drugs are used inappropriately in tertiary care hospitals.5,6

Considering the relevance of medical education for any activity of antifungal stewardship, the main focus of this paper is to present to clinicians a critical review on recognition, diagnosis, and best practice management of invasive candidiasis and mould infections documented in critically ill patients and patients with haematological cancer.

Fungal infections in non-neutropenic patients in intensive care

Epidemiology

Among patients with invasive candidiasis in the intensive-care unit (ICU), two-thirds will have candidaemia, and 80% of non-candidaemic patients will have intra-abdominal candidiasis. Although candiduria has been documented in around 20% of patients in the ICU, associated tissue infection or secondary candidaemia occur in fewer than 5% of patients.2,9–11

Incidence of ICU-acquired candidaemia varies by region and institution: 2–1 per 1000 admissions (range 0.5–6.5) develop such disease in Australia;12 6.7 per 1000 admissions in France;13 and 6.1 per 1000 admissions (range 3.6–9.0) in India.6 Crude mortalities of 17–85% and attributable mortalities of 0–49%, have been reported for ICU-acquired candidaemia.4–6,10–11 Attributable mortalities of 26–60% in intra-abdominal candidiasis are highest in patients with secondary or tertiary peritonitis.4–6

In recognition of the limitations of the International Classification of Diseases, 9th Revision coding, a multicentre US study of 2.57 million ICU patients with invasive aspergillosis yielded a prevalence of invasive aspergillosis of 0.017%, and 46% in-hospital mortality.13 In Europe, 3–7% of ICU patients have proven or probable invasive aspergillosis on the basis of European Organisation for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions for immunocompromised patients,11 with an in-ICU mortality of 87–97%;1 these figures probably underestimate invasive aspergillosis incidence and overestimate mortality.5,6

Lancet Infect Dis 2017
Published Online July 31, 2017
http://dx.doi.org/10.1016/S1473-3099(17)30304-3
See Online/Series
http://dx.doi.org/10.1016/S1473-3099(17)30303-1, http://dx.doi.org/10.1016/S1473-3099(17)30308-0

This is the second in a Series of eight papers about fungal infections.

Department of Medicine, Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil (A L Colombo MD); Central Laboratory Division (LIM03) and Laboratory of Medical Mycology (LIM03), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil (J N de Almeida Junior MD); Department of Infectious Diseases, Peter MacCallum Cancer Center, Melbourne, VIC, Australia, and Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute, Melbourne, VIC, Australia (M A Slavin MD); Department of Microbiology Laboratory Services, ICPMR Pathology West, New South Wales Health Pathology, Westmead and Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead, NSW, Australia (S C-A Chen MD);
Chronic obstructive pulmonary disease, influenza, and decompensated cirrhosis are the leading cause of invasive fungal diseases in the ICU setting. Candida spp are the most common pathogens in fungal infections. Species prevalence varies with geography, institution, case-mix, host risk, and clinical practice. C albicans predominates globally (44–70% of cases), with C tropicalis the most common species in India, Singapore, and Thailand (46% of patients hospitalised with candidaemia). C glabrata is ranked second in the USA, UK, northern Europe (including Finland, Norway, and Denmark), and Australasia. C parapsilosis is ranked second in southern Europe (including Portugal and Spain). In Brazil, C tropicalis and C parapsilosis share equal second position. Candida auris has emerged more recently, causing 5–2% of ICU candidaemias in India. Although species can predict drug susceptibility, local epidemiological patterns vary and affect the value of species prediction.

Overall, more than 95% of C albicans and C parapsilosis isolates remain azole-susceptible, although in one Chinese study, 10% of C albicans isolates and 19% of C parapsilosis isolates were azole-resistant. C tropicalis is usually azole-susceptible (roughly 97% of isolates), but 15% of blood isolates are resistant in Australia (SC-A Chen, unpublished). C glabrata, C krusei, and C auris are intrinsically less susceptible than other species to fluconazole, with 4–15% of isolates azole cross-resistant. Clinical echinocandin resistance is more accurately predicted by mutations in FKS genes than by minimum inhibitory concentrations. In many countries, echinocandin resistance is uncommon, but in some US centres, resistance rates of 18–20% have been reported. Furthermore, up to 10% of azole-resistant C glabrata isolates are echinocandin resistant. Higher echinocandin minimum inhibitory concentrations in C parapsilosis are due to naturally occurring polymorphisms in FKS genes.

Approximately 95% of invasive aspergillosis is due to the Aspergillus fumigatus complex. A higher proportion of Aspergillus terreus disease has been reported in Austria. In Europe, azole resistance is 3–3% on average (0–26% in different countries).

Risks
Urinary catheters are the main risk factor for candiduria, which might lead to ascending upper urinary tract infection. Additional risk factors for candiduria include female sex, presence of diabetes, and proximate use of broad-spectrum antimicrobials.

Risk factors for invasive candidiasis in the ICU are summarised in the appendix. To better target early antifungal therapy and improve outcomes, prediction rules that identify populations at increased risk of invasive candidiasis have been derived. These incorporate clinical or Candida spp colonisation parameters (table 1).

Although effective in excluding risk of invasive candidiasis, the positive predictive value (PPV) of these prediction rules is often low, and they might not do well outside their derivation cohorts. A ten-point summation score identified three patient categories: those at high risk, in whom prophylaxis should be considered (score ≥6, 4–8% of cohort, PPV 11–7%); those at low risk, in whom prophylactic or empirical antifungal therapy is not required (score ≤2, 43–1% of cohort, PPV 0–24%); and those at intermediate risk (score ≥3–5, 52–1% of cohort, PPV 1–46%), for whom further investigation, including use of biomarkers, should be considered.

Invasive pulmonary aspergillosis is most common in severe chronic obstructive pulmonary disease requiring high dose steroid therapy, but it can complicate H1N1 influenza and Child-Pugh C hepatic cirrhosis (appendix).
more than 70% of cases. Cultures should be obtained from blood, central lines, abdomen, and probable sites of metastatic infection. To optimise blood culture sensitivity, collection of 40–60 mL of blood from adults is recommended. Culture-based diagnosis is problematic because it is slow (1–7 days) and has poor sensitivity. Only about 50% of cases of invasive candidiasis are candidaemic; other bacteria coexist in approximately 20% of cases. Intra-abdominal candidiasis, the sensitivity of intra-abdominal fluid or cultures from infected sites is less than 50%, and only 4–20% of cases will be candidaemic. Concurrent bacterial infection is common (roughly 70% of cases). In secondary peritonitis, Candida spp can be visualised by direct microscopy in peritoneal fluid and cultured. Because of a high incidence of candida colonisation, growth from drain fluid is only diagnostic if the drain has been in place for less than 24 h.

Rapid diagnostic methods (eg, PCR) are not more sensitive than culture (both have a limit of detection of one to five colony forming units per mL, depending on the quantity of blood sampled), but accelerate diagnosis. Sensitive multiplex PCRs that distinguish common fungal species have been developed in-house and commercially. Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry enables rapid speciation once fungal growth is evident, and has also been used for direct identification of yeasts in blood cultures applying commercial (SepsiTyper, Bruker Daltonics; Bremen, Germany) or in-house protein extraction protocols. An automated system that combines PCR and T2 magnetic resonance relaxivity (T2Candida, T2Biosystems; Lexington, MA, USA) is applicable to anticoagulated blood and appears promising; using spiked samples, the detection limit was

Clinical presentation and diagnosis
In candiduria, colonisation of indwelling urinary catheters is common. Routine diagnostic methods detect bacteria and yeasts, although growth of C glabrata can take 72 h. Neither pyuria nor quantitative cultures distinguish colonisation from infection, hence findings such as unexplained fever, leucocytosis, and coexisting risk factors for invasive candidiasis should be investigated. Imaging of the urinary tract (ultrasound or CT scan) might reveal renal abscesses, hydronephrosis, urinary tract obstruction, or fungus balls.

Invasive candidiasis typically presents with fungaemia (84–90%) 8–15 days after ICU admission, or intra-abdominal candidiasis. In candidaemia, chorioretinitis, although not clinically specific, occurs within 10–14 days in 5–16% of cases; endophthalmitis (with vitreal involvement) is uncommon (1·6%), and haematogenous renal candidiasis and endocarditis each occur in fewer than 5% of cases.

Candidaemia usually originates from biofilms on indwelling intravascular devices or the gastrointestinal tract, and localised infection should be sought. However, loss of mucosal integrity due to ischaemia-reperfusion syndrome, together with a microbiome altered by broad spectrum antimicrobial use, or mucosal atrophy associated with bowel rest and prolonged total parenteral nutrition, promote clinically silent translocation.

Clinical features of intra-abdominal candidiasis are non-specific; patients with recurrent gastrointestinal tract perforations, necrotising pancreatitis, or repeated gastrointestinal tract surgery are at highest risk. Secondary peritonitis or abdominal abscesses account for more than 70% of cases. Cultures should be obtained from blood, central lines, abdomen, and probable sites of
one to three colony forming units per mL, sensitivity 91% and specificity more than 99%, with a turnaround time of 4–5 h. Further clinical investigation is needed to establish the role of non-culture-based diagnostics in the workup of patients at high risk of invasive candidiasis. It has been suggested that diagnostic triggers include patients at high risk of intra-abdominal candidiasis,‡ with pretest probabilities of 15–35% for invasive candidiasis, or ICU patients identified as being at intermediate risk of invasive candidiasis.³³

Diagnosis of invasive pulmonary aspergillosis in ICU populations requires a high index of suspicion. Patients with risk factors (appendix) who develop pulmonary infiltrates despite receiving broad-spectrum antibiotics, require investigation for invasive pulmonary aspergillosis.

### Table 2: Non-culture based methods for diagnosis of invasive candidiasis and invasive bronchopulmonary aspergillosis in non-neutropenic critically ill patients

<table>
<thead>
<tr>
<th>Method and reference</th>
<th>Specimen (cutoff)</th>
<th>Test performance</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive candidiasis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,3-β-D-glucan Serum (&gt;80 pg/mL) *</td>
<td>Pooled:1,10 sensitivity 65–81%; specificity 57–83%; PPV 22–63%; NPV 77–96%;</td>
<td>Time-consuming, not user-friendly, and costly. All materials used during the procedure must be free of glucan. Whole plate must be used when doing the test, even if only a few samples are being analysed. Two consecutive positive samples increase specificity and PPVs. False positives: blood transfusions, blood-derived products including immunoglobulins, haemodialysis or haemofiltration, some Gram-positive bacteria, β-lactam antibiotics, cellulose dressings, contamination of specimens by organic material, and enteral nutrition. False negatives: antifungal therapy, sanctuary sites or poorly vascularised sites of infection, and Candida parapsilosis infection.ᦁ</td>
<td></td>
</tr>
<tr>
<td>Mannan-Ag and mannan-Ab Serum (mannan-Ag ≥0.5 mg/mL, mannan-Ab ≥10 AL/mL)</td>
<td>Pooled:11,12 sensitivity 54–94%; specificity 59–95%; PPV 17–94%; NPV 89–94%;</td>
<td>C. neoformans and Candida spp release lower amounts of mannan and patients infected by these species might have negative results.⁴⁴</td>
<td></td>
</tr>
<tr>
<td>Multiplex real-time PCR (probes targeting ribosomal DNA) Whole blood, serum, plasma</td>
<td>Pooled:13 sensitivity 84–96%; specificity 33–97%; PPV 27–93%; NPV 87–99%;</td>
<td>More than one PCR test per patient might be associated with higher specificity. DNA extraction with commercial kits might be associated with higher specificity than most methods based on mechanical lysis.⁴⁵</td>
<td></td>
</tr>
<tr>
<td>T2 Candida panel (multiplex PCR-based method with detection of amplified product with magnetic resonance) Whole blood</td>
<td>Sensitivity 91%; specificity 98%; PPV 84%; NPV 99%*⁴⁶</td>
<td>Probes designed to detect Candida albicans or Candida tropicalis, C. parapsilosis, and C. krusei or Candida glabrata. More extensive validation is required, including a larger number of patients with candidaemia documented by blood cultures.</td>
<td></td>
</tr>
<tr>
<td><strong>Invasive aspergillosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,3-β-D-glucan Serum (&gt;80 pg/mL) *</td>
<td>Pooled:11,12 sensitivity 48–80%; specificity 76–79%; PPV 44–48%; NPV 79–94%;</td>
<td>Utility for diagnosis of invasive pulmonary aspergillosis in critically ill patients is lower than that of galactomannan determination in BALF. In patients with COPD, initial negative tests might become positive on repeat testing.⁴⁷ False positive results: treatment with β-lactams (eg, piperacillin and tazobactam, and amoxicillin and clavulanate; eventually found in generic formulations of the antibiotics), presence of other invasive mycoses (eg, Penicillium spp, histoplasmosis, or blastomycosis), or patients with intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>Galactomannan Serum (ODI ≥0.5)</td>
<td>Pooled:11,12 sensitivity 41–78%; specificity 89–100%; PPV 55–100%; NPV 79–89%;</td>
<td>Utility for diagnosis of invasive pulmonary aspergillosis in critically ill patients is lower than that of galactomannan determination in BALF. In patients with COPD, initial negative tests might become positive on repeat testing.⁴⁷ False positive results: treatment with β-lactams (eg, piperacillin and tazobactam, and amoxicillin and clavulanate; eventually found in generic formulations of the antibiotics), presence of other invasive mycoses (eg, Penicillium spp, histoplasmosis, or blastomycosis), or patients with intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>Galactomannan BALF (ODI ≥0.5)</td>
<td>Pooled:11,12 sensitivity 80–89%; specificity 47–93%; PPV 47–73%; NPV 89–95%;</td>
<td>Higher cutoff (ODI ≥0.8) improved specificity in critically ill patients with COPD.⁴⁷</td>
<td></td>
</tr>
<tr>
<td>Galactomannan BALF (ODI ≥1.0)</td>
<td>Sensitivity 80%; specificity 97%; PPV 89%; NPV 95%*⁴⁷</td>
<td>Despite good performance, insufficient multicentre validation.</td>
<td></td>
</tr>
<tr>
<td>Lateral-flow device BALF (qualitative: positive or negative)</td>
<td>Sensitivity 80%; specificity 81%; PPV 49%; NPV 96%*⁴⁷</td>
<td>Insufficient comparison with other non-culture-based methods and multicentre validation.</td>
<td></td>
</tr>
<tr>
<td>Multiplex real-time PCR: AsperGenius (probes targeting ribosomal DNA) BALF (C &lt;15)</td>
<td>Sensitivity 80%; specificity 93%; PPV 80%; NPV 93%*⁴⁷</td>
<td>Despite good performance, insufficient multicentre validation. Approved by the European Union for in-vitro diagnosis. Also detects CPS1A mutations in Aspergillus fumigatus.</td>
<td></td>
</tr>
</tbody>
</table>

For references, see supplementary material. PPV—positive predictive value. NPV—negative predictive value. Ag—antigen. Ab—antibody. BALF—bronchoalveolar fluid. ODI—optical density index. COPD—chronic obstructive pulmonary disease. Ct—optimal threshold cycle value. *Cutoff for the Fungitell assay (Associates of Cape Cod, East Falmouth, MA, USA). Other assays have been commercialised in Japan with different cutoff values: Fungitec G (Seikagaku Corporation, Tokyo, Japan), β-glucan test (Wako Pure Chemical Industries, Tokyo, Japan), and BIGSTAR β-glucan test (Maruha, Tokyo, Japan). ‡Based on a candidaemia prevalence of 10%.
Thoracic CT scans usually reveal patchy or nodular lesions, necrotic cavities, or both. Halo and air-crescent signs, or wedge consolidation, occur in less than 20% of cases. In one study, the specificity of multiple nodules distributed along bronchovascular bundles on chest CT was 92–5%.7 Serum galactomannan assays do poorly in non-neutropenic patients with invasive aspergillosis, but might be of value when measured in bronchoalveolar lavage (BAL) fluid (table 2).20

In patients with endotracheal aspirates positive for *Aspergillus* spp, colonisation should be distinguished from invasive pulmonary aspergillosis. A validated algorithm,21 which defined probable invasive pulmonary aspergillosis (positive endotracheal aspirates, compatible clinical signs, abnormal thoracic imaging, and either host factors or positive BAL fluid for *Aspergillus* spp on direct microscopy and culture) and proven invasive pulmonary aspergillosis (as per EORTC/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group definitions), yielded PPVs of 61% and negative predictive values (NPVs) of 92%.22

**Clinical management in the ICU**

In candiduria, high urinary and tissue concentrations make fluconazole the first-line drug for prophylaxis in high-risk groups (eg, patients with neutropenia or post-urinary tract instrumentation), and for treatment of urinary tract infections caused by susceptible strains. Colonised indwelling catheters should be removed when feasible.7 Amphotericin B deoxycholate bladder irrigation (50 mg/L sterile water daily for 5 days) might cure cystitis due to fluconazole-resistant species or in renal failure, when urine fluconazole levels are low.50 Removal of fungus balls and replacement of stents or nephrostomy tubes is recommended.7

In candidaemia and intra-abdominal candidiasis, although fluconazole prophylaxis reduces invasive candidiasis, its effect on mortality is unclear. Prophylaxis with caspofungin11 or micafungin16 did not reduce invasive candidiasis in two studies, one of which was in patients with a more than 30% risk of intra-abdominal candidiasis.13 Universal prophylaxis is not recommended.7

Despite an absence of proven benefit, empirical antifungal therapy could be considered in high-risk patients (table 3 and appendix) with sepsis without a clear source;12 such therapy might be ceased in patients with negative serum biomarkers and absence of multifocal colonisation,12,14 or those at low risk on the basis of a published risk prediction rule.7

Two consecutively positive serum 1,3-β-D-glucan results can predict invasive candidiasis.35 Antifungal pre-emptive therapy driven by positive serum 1,3-β-D-glucan results could be especially useful in patients at highest risk of intra-abdominal candidiasis, such as patients with recurrent gastrointestinal tract perforation or necrotising pancreatitis.39 Prospective, randomised trials are needed to substantiate this approach.

Echinocandins are the preferred first-line therapy for proven invasive candidiasis.26 In patients with susceptible *Candida* spp, triazoles might be initiated after clinical improvement and negative blood cultures. Lipid amphotericin B formulations should be considered in patients with CNS involvement, endocarditis, or intolerance or resistance to echinocandins.7,22

In invasive pulmonary aspergillosis, empirical antifungal therapy is warranted, since treatment of possible invasive pulmonary aspergillosis has resulted in a shorter ICU stay, lower costs, and better outcomes.20 A pre-emptive approach, based on early measurement of galactomannan in BAL fluid, appears promising.22

Voriconazole is the first-line therapy for invasive pulmonary aspergillosis.8 Because of metabolism of voriconazole by hepatic CYP2C19 P450, drug interactions are potentially problematic and therapeutic drug monitoring is recommended (table 3). Amphotericin B lipid formulation (except for *A terreus*) and isavuconazolium sulfate are alternatives if voriconazole is contraindicated or not tolerated.47

Intravenous therapy should be de-escalated to one oral agent, typically continued for 6–12 weeks, after clinical improvement, but should be tailored to clinical and radiological responses.8 There are no published data correlating clinical responses with serum galactomannan levels in the setting of non-neutropenic critically ill patients.8

**Fungal infections in patients with haematological cancer**

**Epidemiology and risks**

Evolving treatments for haematological malignancy and allogeneic haemopoietic stem-cell transplantation (HSCT) affect risk and timing of invasive fungal infections (IFIs).34 Reduced-intensity conditioning regimens have shortened the duration of neutropenia and shifted IFI occurrence later post-transplantation.98 Alternative donor sources (umbilical cord blood, matched unrelated, or mismatched unrelated donors) have expanded HSCT availability but increased the risk of IFIs.1 In critically ill patients, the spectrum of IFI is influenced by patterns of antifungal use,90 geographical factors,92 patient mix, and type and number of HSCTs.9

Risk factors for IFI include underlying malignancy, status and treatment of underlying malignancy, other comorbidities, performance status, and environmental exposure.93–95 Risk factors evolve and should constantly be reviewed to optimise antifungal prophylaxis and empirical therapy.

**Invasive candidiasis**

Candidaemia in haematological malignancy has a mortality of 40%.96 Disseminated invasive candidiasis is rare, probably because of widespread use of antifungal prophylaxis.97 HSCT recipients in the USA had an
### Table 3: Main strategies for the management of invasive candidiasis conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>First-line therapy</th>
<th>Alternatives</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Candidaemia</strong></td>
<td><strong>Targeted therapy</strong></td>
<td></td>
<td>Despite a higher minimum inhibitory concentration of echinocandins against Candida parapsilosis isolates, outcomes of echinocandin-treated patients are similar. Antifungal susceptibility should be established; echinocandins can be used initially if the patient is not critically ill and resistance is unlikely, and can be used as a stepdown from echinocandin after 5–7 days if the patient is clinically stable, the isolate is susceptible, and blood cultures are negative on therapy. Voriconazole can be considered for isolates not susceptible to echinocandin, but drug-drug interactions, limitations of intravenous formulation in renal impairment, and need for therapeutic drug monitoring should be considered; therapy should be kept to a minimum of 2 weeks after the first negative blood culture in cases without metastatic complications; eye examination is required for all patients; central venous catheters should be removed as early as possible in the course of candidaemia when the source is presumed to be the catheter.</td>
</tr>
<tr>
<td><strong>Empirical therapy</strong></td>
<td></td>
<td></td>
<td>Value of empirical therapy is unproven but is reasonable for patients at high risk according to one of the predictive rules for invasive candidiasis, with no explanation for fever; treatment should be ceased if there is no evidence of colonisation in multiple sites or if biomarkers are measured and tests are consecutively negative; otherwise, therapy should be kept to a minimum of 2 weeks.</td>
</tr>
<tr>
<td><strong>Prophylaxis</strong></td>
<td>Fluconazole: 400 mg (6 mg/kg) daily</td>
<td>Echinocandins (caspofungin: 70 mg loading dose, then 50 mg daily; micafungin: 100 mg daily; anidulafungin: 200 mg loading dose, then 100 mg daily)</td>
<td>Indicated only in high-risk patients (threshold recommended by experts varies, &gt;10% incidence); echinocandin is not better than fluconazole, and evidence for use is weak.</td>
</tr>
<tr>
<td><strong>Intra-abdominal candidiasis</strong></td>
<td><strong>Targeted therapy</strong></td>
<td></td>
<td>Choice of antifungal therapy should be the same as for candidaemia; duration of therapy should be individualised according to clinical response and source control; source control includes drainage of abscesses and necrotic tissue debridement.</td>
</tr>
<tr>
<td><strong>Empirical therapy</strong></td>
<td></td>
<td></td>
<td>Although unproven, treatment should be considered if clinical evidence of refractory sepsis, intra-abdominal infection, recent abdominal surgery, anastomotic leaks, or necrotising pancreatitis is present; choice of antifungal therapy should be the same as for candidaemia.</td>
</tr>
<tr>
<td><strong>Prophylaxis or pre-emptive therapy</strong></td>
<td>No recommendation</td>
<td>No recommendation</td>
<td>Insufficient evidence to support the use of prophylaxis or pre-emptive treatment, even in subgroups of high-risk patients.</td>
</tr>
<tr>
<td><strong>Endocarditis</strong></td>
<td>Liposomal amphotericin B (3–5 mg/kg daily, amphotericin B lipid complex 3–5 mg/kg daily as alternative) plus or minus fluconazole (25 mg/kg four times daily)</td>
<td>High dose echinocandin (caspofungin 150 mg daily, micafungin 150 mg daily, anidulafungin 200 mg daily)</td>
<td>Azoles can be used for stepdown therapy provided that patients are clinically stable, isolates are susceptible and blood cultures are negative; valve replacement is recommended; duration of therapy should be at least 6 weeks after surgery; for patients who cannot undergo valve replacement or those with prosthetic valve endocarditis, chronic suppression with fluconazole (400–800 mg per day) is recommended, for infections related to implantable cardiac devices (implantable cardioverter defibrillator, ventricular assist device, pacemaker), antifungal therapy is the same as that recommended for endocarditis and disposals have to be removed.</td>
</tr>
<tr>
<td><strong>Endophthalmitis</strong></td>
<td>Fluconazole: 800 mg (12 mg/kg) daily loading dose, then 400–800 mg (6–12 mg/kg) daily; voriconazole: 400 mg (6 mg/kg) loading dose twice daily for two doses, then 300 mg (4 mg/kg) twice daily</td>
<td>Liposomal amphotericin B (5 mg/kg daily, amphotericin B lipid complex 5 mg/kg daily as alternative) plus or minus fluconazole (25 mg/kg four times daily)</td>
<td>Duration of treatment should be at least 4–6 weeks, with the final duration depending on resolution of the lesions as determined by repeated ophthalmological examinations; with vitreal involvement, additional intravitreal injection of either amphotericin B deoxycholate (5–10 μg per 0.1 mL sterile water, or voriconazole (100 μg per 0.1 mL sterile water or normal saline), is recommended; echinocandins penetrate poorly into the eyes.</td>
</tr>
<tr>
<td><strong>Meningitis</strong></td>
<td>Liposomal amphotericin B (5 mg/kg daily) plus or minus fluconazole (25 mg/kg four times daily) or fluconazole 400 mg (6 mg/kg) daily</td>
<td>Fluconazole: 400–800 mg (6–12 mg/kg daily); intravenous voriconazole: 400–800 mg (6–12 mg/kg daily)</td>
<td>The optimal length of therapy has not been evaluated; several weeks of therapy are suggested before transitioning to oral azole therapy, fluconazole can be an option for stepdown therapy; infected CNS devices should be removed, if infected devices cannot be removed, amphotericin B deoxycholate could be administered through the device (0.03–0.50 mg in 2 mL 5% dextrose in water); echinocandins and posaconazole penetrate poorly into the CNS; voriconazole should be considered for stepdown therapy for fluconazole-resistant Candida spp isolates.</td>
</tr>
</tbody>
</table>

For references, see supplementary material.
invasive candidiasis incidence of 1% at 6 months and 1%-1% at 12 months, whereas in Europe, fungaemia occurred in 1-55% of HSCT recipients, and 90% of cases were due to Candida spp.6,65

Breakthrough candidaemia (a positive blood culture after ≥3 days of antifungal therapy) accounts for up to 50% of candidaemias.6,65 Previous antifungal exposure increases the likelihood of fluconazole, echinocandin, or multidrug resistance.6,66

Established candidaemia risk factors (appendix), especially neutropenia and disruption of the gastrointestinal tract mucosa after chemotherapy, radiotherapy, or surgery, also apply to patients with haematological malignancy.6,66 At the time of fungaemia, most patients with haematological malignancy have acute leukaemia in relapse and bone marrow hypoplasia.6,66 Yeasts other than Candida spp, such as Malassezia spp, Rhodotorula spp, Saccharomyces spp, and Trichosporon spp, are uncommon pathogens but crude mortalities could be up to 70%.6,67 Infections often originate from intravascular catheters. The intrinsically highly drug resistant Trichosporon spp should be considered in breakthrough infections.6,66 As with other IFIs, there are geographical variations in incidence: Trichosporon spp are more prevalent in warm, moist climates.6,66

Invasive mould infections
Rates of invasive mould infections, most commonly invasive pulmonary aspergillosis, are similar in haematological malignancy and HSCT patients globally, and are higher than invasive candidiasis.6,69 Invasive mould infections occur in an estimated 11–18% of patients with acute myeloid leukaemia,6,70 5–10% of allogeneic HSCT recipients,6,70 up to 10% of patients with acute lymphoid leukaemia,6,68 and in heavily treated patients with chronic lymphoid leukaemia.6,69

Intensive chemotherapy regimens for adult acute lymphoid leukaemia probably explain the apparent increase in infection in these patients, in whom frequent vincristine administration excludes mould-active azole prophylaxis.72 Mould infections occur in less than 2% of autologous HSCT recipients.6,70 Much higher incidences of haematological malignancy and HSCT-associated IFIs (27%) were noted in a centre undertaking aggressive diagnostic approaches.74 A fumigatus complex causes most mould infections; however, Aspergillus flavus is more frequent in tropical climates69 and A terreus in Austria.71

Mucormycosis ranks second in some centres,72 particularly in patients with sinusitis, diabetes, or corticosteroid use, although in the USA mucormycosis accounted for only 8% of fungal infections and aspergillosis accounted for 43%.72 In Brazil, fusariosis frequency is second to aspergillosis.73 Mould infections other than aspergillosis present later after HSCT or after extensive antifungal exposure,74 and mortality is 70–80%.6,75 By contrast, mortality from aspergillosis has fallen (≤40%), probably because of improved diagnostics and better tolerated treatments.73

Although the use of molecular methods has resulted in identification of multiple genera and genotypes of moulds in some clinical samples and histopathology specimens,76,77 the prevalence and clinical relevance of such findings need further investigation.

Risk factors for IFIs include environmental exposure and host factors, such as status and treatment of underlying malignancy, comorbidities, history of previous fungal infections, and exposure to antifungal prophylaxis (panel).6,68,69

Panel: Host, disease, treatment, and environmental factors associated with invasive fungal disease in haematological malignancy and stem-cell transplant recipients

Patient factors
- Age
- Hypoalbuminaemia*
- Genetics*
- Poor performance status (Eastern Cooperative Oncology Group performance status ≥2)
- Chronic obstructive pulmonary disease*
- Diabetes and hyperglycaemia

Disease-related factors
- Acute myeloid leukaemia remission-induction chemotherapy
- Adverse cytogenetic or gene mutation profile
- Allogeneic stem cell transplants
- Transplant factors (cord blood, haploidentical, mismatched donor)
- Pre-transplantation factors (invasive fungal disease before transplantation, active leukaemia at transplantation)
- Post-transplantation factors (graft vs host disease—high grade acute and chronic extensive, cytomegalovirus disease, cytomegalovirus viraemia,* viral respiratory tract infections, iron overload)
- Acute lymphoblastic leukaemia therapy*
- Multiple lines of treatment in lymphoproliferative disorders*

Treatment-related factors
- Prolonged neutropenia (longer than 2–3 weeks)
- Corticosteroids
- Lymphopenia or lymphocyte dysfunction
- Monocytopenia
- Cytarabine
- Ganciclovir*
- Alemtuzumab*
- High-grade oesophagitis (>2 as per WHO scale)*

Environmental factors
- Hospital building works
- High-efficiency particulate air filtration (protective)
- Laminar airflow (protective)
- Dry weather with high temperatures
- Ambient mould spore counts*
- Living in rural areas*
- High-risk occupation or activity (farming, construction, gardening)
- Smoking

For references, see supplementary material. *Risk not well characterised or quantified, or identified in only one study.
Clinical presentation and diagnosis of yeast fungaemia

Patients with yeast fungaemia present non-specifically, with fever unresponsive to antibiotics, but deep-seated infection in the liver, spleen, heart, and eye might also occur. Skin lesions (<10% of cases) appear as erythematous small papules and macules. Eye involvement (<10%) and hepatosplenic candidiasis typically occur upon recovery from neutropenia (<5% of cases). Rapid pathogen identification and antifungal susceptibility tests are essential to direct antifungal therapy.79

Clinical presentation

Invasive mould diseases can involve almost any body site, but fungal pneumonitis is the most common presentation, together with sinusitis and fungaemia. Other clinical entities, clinical and radiological images, and laboratory findings are presented in the appendix. The lung is the most common site of mould diseases. For fungal pneumonia, asymptomatic colonisation should be distinguished from tracheobronchitis, invasive lung disease, empyema, and disseminated disease. Infection might begin insidiously, with a persistent cough, fever, or malaise. Tracheobronchitis causes hoarseness, stridor, and airway obstruction. Haemoptysis, chest pain, and dyspnoea might be present. As clinical features are not pathogen-specific, aggressive diagnostic investigation is required and bronchoscopy or lung biopsy or aspirate might be needed.

Radiographic characteristics of invasive fungal pneumonia include nodules, masses, or infiltrates. On CT, surrounding ground glass opacities, halo sign (appendix), central air cavity, or air bronchograms are characteristic, especially of invasive aspergillosis. Multiple nodules (ten or more), pleural effusions, and reverse halo sign are more likely in pulmonary mucormycosis than in invasive pulmonary aspergillosis (appendix). High-resolution CT angiography can detect angio-invasion, and vessel occlusion was reported to be highly sensitive for diagnosis of invasive pulmonary aspergillosis. Additionally, use of aspergillus-specific labelled monoclonal antibody with PET scanning is expected to revolutionise the diagnosis of invasive pulmonary aspergillosis, by differentiating it from other fungal (and bacterial) pneumonitis.

For invasive fungal sinusitis, aspergillosis remains the commonest pathogen in immunocompromised people, but fusarium, Scedosporium prolificans (originally named Lomentospora prolificans), and mucorales also cause sinus, sino-pulmonary, and orbital-cerebral disease. Symptoms result from local invasion of sinus tissue and cranial nerves, and the brain and intracranial vascular structures are commonly involved. Typical physical findings include sinus tenderness, ophthalmoplegia, and proptosis. Nasofibroscopy might reveal pale lesions in the nasal mucosa, suggestive of local ischaemia, which usually precede black eschar-like lesions. Necrotic black eschar-like lesions in the oral cavity and palate are a late sign. CT scans or MRI show evidence of soft tissue masses and bony destruction. The aetiological fungus should be sought in biopsy or aspirated material.

All pathogenic moulds are angioinvasive. Fusarium spp and Scedosporium spp, but not Aspergillus spp, undergo intravascular adventitious sporulation, which releases spores into the bloodstream and results in fungaemia (appendix). Blood cultures are positive in 60–75% of cases of disseminated fusariosis and 30–35% of cases of disseminated scedosporiosis. Conversely, fungaemia is rare in invasive aspergillosis and mucormycosis.

Diagnostic strategies

In fungal respiratory tract infections, since new technologies are not yet applicable to all fungi, histopathological examination, culture, and other conventional diagnostic methods remain the cornerstone of diagnosis, despite being slow and poorly specific. Molecular and antigen-based diagnostics should also be done when possible. Dried or preserved fungal hyphae can be visualised histopathologically using stains such as Gomori’s methenamine silver or periodic acid Schiff, whereas in fresh specimens, fluorescent dyes such as calcifiouor-white reveal hyphae typical of IFIs and might help distinguish between hyalohyphomycetes and mucorales. Immunohistochemical techniques using fungus-specific fluorescent antibodies are promising, but not yet validated.

Panfungal PCR, DNA sequencing assays, or fungal species-specific assays can identify pathogens directly in tissue, blood, serum, or sputum. These methods were sensitive and specific in small case series, but are mostly unstandardised.

Mucorales DNA has been detected with good sensitivity in fresh and paraffin-embedded tissue specimens using conventional and real-time PCR targeting 18S and 28S rRNA. A sensitive, multiplex PCR also appears promising for early detection of mucorales in blood.

Fungal biomarkers may be useful for screening and diagnostic strategies. The combination of galactomannan and aspergillus PCR done in BAL fluid obtained from haematology patients during the high-risk period for invasive aspergillosis or early in the course of invasive aspergillosis has proven sensitive and specific. Serum galactomannan testing might be less sensitive than BAL galactomannan in patients with invasive pulmonary aspergillosis (colonisation is not easily distinguished from invasive infection). These tests should always be interpreted along with clinical and radiological information, and consideration should be taken for causes of false positive results.

There are no biomarkers specific for non-aspergillus mould diseases; the galactomannan test shows cross reactivity between Aspergillus spp and Fusarium spp. Similarly, 1,3-β-D-glucan, a cell wall constituent of many fungi, can be positive in invasive aspergillosis and
non-aspergillus mould diseases, with the exception of mucormycosis.9 The clinical use of 1,3-B-D-glucan might be its high NPV, when it can be used to exclude IFIs.98

Antifungal therapeutic strategies for patients with haematological cancer

Echinocandins are the preferred first-line therapy for patients with invasive candidiasis. Lipid formulations of amphotericin B are alternatives in patients with CNS involvement, patients intolerant to echinocandins, or infections due to azole-resistant candida strains.

Guidelines recommend mould-active prophylaxis, mainly with new triazoles or inhaled amphotericin B, in high-risk haematology patients.99,100 However, these strategies are best directed to patients with a more than 10% risk for developing invasive aspergillosis, to offset the cost and toxicity of antifungals, and risk of future antifungal resistance.101,102

For patients at intermediate risk for developing invasive aspergillosis (3–10%), monitoring of serum galactomannan and aspergillus PCR is useful for early diagnosis of invasive aspergillosis when combined with aggressive CT

---

## Table 4: Principles for the management of invasive mould diseases

<table>
<thead>
<tr>
<th>Strategy</th>
<th>First-line therapy</th>
<th>Alternatives</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive aspergillosis</strong>&lt;sup&gt;+&lt;/sup&gt; Targeted therapy</td>
<td>Intravenous voriconazole: 400 mg (6 mg/kg) loading dose twice daily for 2 doses, then 300 mg (4 mg/kg) twice daily&lt;sup&gt;[8]&lt;/sup&gt;</td>
<td>Liposomal amphotericin B: 3–5 mg/kg daily (as alternative, amphotericin B lipid complex 5 mg/kg daily); isavuconazole: 200 mg every 8 h for 2 days, then 200 mg daily if voriconazole is contraindicated or not tolerated&lt;sup&gt;[9,10]&lt;/sup&gt;</td>
<td>Intravenous posaconazole, 300 mg every 12 h on day 1, then 300 mg daily, is undergoing evaluation as a first-line therapy. Aspergillus terreus should be treated with an azole rather than polyene antifungal, antifungal susceptibility profile should be determined, particularly where environmental azole resistance is prevalent, where there has been previous antifungal exposure, or when the patient is failing therapy. In regions with environmental resistance rates of ≥10%, a liposomal amphotericin B or voriconazole-echinocandin combination were favoured as initial therapy unless the patient had CNS aspergillosis, in which case liposomal amphotericin B and fluconazole is recommended&lt;sup&gt;[11]&lt;/sup&gt;; drug-drug interactions, limitations of intravenous formulation in renal impairment, and need for therapeutic drug monitoring should be considered; therapy should be for a minimum of 6–12 weeks depending on response and host immune recovery&lt;sup&gt;[12]&lt;/sup&gt; after clinical improvement, maintenance therapy can be done with oral formulation of voriconazole, posaconazole, or isavuconazole.</td>
</tr>
<tr>
<td><strong>Mucormycosis</strong> Targeted therapy</td>
<td>Liposomal amphotericin B: 5 mg/kg daily (as alternative, amphotericin B lipid complex 5 mg/kg daily if there is no CNS invasion)&lt;sup&gt;[13]&lt;/sup&gt;</td>
<td>Intravenous posaconazole: 300 mg every 12 h on day 1, then 300 mg daily, or intravenous isavuconazole: 200 mg every 8 h for 2 days, then 200 mg daily for intolerance or salvage therapy&lt;sup&gt;[10]&lt;/sup&gt;</td>
<td>Prompt and aggressive surgical debridement of necrotic tissue is required; doses of liposomal amphotericin B of up to 10 mg/kg per day have been suggested for refractory disease&lt;sup&gt;[14]&lt;/sup&gt;; after clinical improvement, maintenance therapy can be with oral formulation of posaconazole or isavuconazole.</td>
</tr>
<tr>
<td><strong>Fusariosis</strong> Targeted therapy</td>
<td>Liposomal amphotericin B: 3–5 mg/kg daily (as alternative, amphotericin B lipid complex 5 mg/kg daily); or intravenous voriconazole: 400 mg (6 mg/kg) loading dose twice daily for 2 doses, then 300 mg (4 mg/kg)&lt;sup&gt;[15]&lt;/sup&gt;</td>
<td>Intravenous posaconazole: 300 mg every 12 h on day 1, then 300 mg daily, or intravenous isavuconazole: 200 mg every 8 h for 2 days, then 200 mg daily&lt;sup&gt;[10]&lt;/sup&gt;</td>
<td>Combination therapy might be considered for persistently neutropenic patients failing therapy; surgical debridement of localised infection should be considered; therapeutic drug monitoring for voriconazole and posaconazole should be considered;&lt;sup&gt;[16]&lt;/sup&gt; after clinical improvement, maintenance therapy can be with oral formulation of voriconazole, posaconazole, or isavuconazole.</td>
</tr>
<tr>
<td><strong>Scedosporiosis</strong> Targeted therapy</td>
<td>Intravenous voriconazole: 400 mg (6 mg/kg) loading dose twice daily for 2 doses, then 300 mg (4 mg/kg)&lt;sup&gt;[17]&lt;/sup&gt;</td>
<td>Intravenous posaconazole: 300 mg every 12 h on day 1, then 300 mg daily, or intravenous isavuconazole: 200 mg every 8 h for 2 days, then 200 mg daily&lt;sup&gt;[10]&lt;/sup&gt;</td>
<td>Combination therapy with addition of tib pilgrim or an echinocandin to voriconazole should be considered for Scedosporium prolificans infection&lt;sup&gt;[18]&lt;/sup&gt;; surgical debridement of localised infection should be considered; therapeutic drug monitoring for voriconazole and posaconazole should be considered; after clinical improvement, maintenance therapy can be with oral formulation of voriconazole or posaconazole.</td>
</tr>
<tr>
<td><strong>Mould infection</strong> Empirical therapy</td>
<td>Liposomal amphotericin B: 3–5 mg/kg daily (as alternative, amphotericin B lipid complex 5 mg/kg daily); echinocandin (caspofungin: loading dose of 70 mg, then 50 mg daily&lt;sup&gt;[19]&lt;/sup&gt;)</td>
<td>Intravenous voriconazole: 400 mg (6 mg/kg) loading dose twice daily for 2 doses, then 300 mg (4 mg/kg)&lt;sup&gt;[14]&lt;/sup&gt;</td>
<td>Rationale of empirical therapy is unproven, but is reasonable for patients at high risk of mould infection with no explanation for ongoing fever and clinical deterioration, or clinical symptoms suggestive of mould infection, while investigations such as CT scanning of chest or sinuses, BAL including non-culture-based diagnostics, or lung biopsy, are undertaken; empirical therapy should be ceased if there is no evidence of invasive mould infection on investigation; amphotericin B lipid formulation or voriconazole are preferred to an echinocandin&lt;sup&gt;[20]&lt;/sup&gt;; after clinical improvement, maintenance therapy can be with oral formulation of voriconazole.</td>
</tr>
<tr>
<td><strong>Mould infection</strong> Prophylaxis</td>
<td>Posaconazole: tablet or intravenous formulation, 300 mg 12 hourly day 1, then 300 mg daily&lt;sup&gt;[21]&lt;/sup&gt;</td>
<td>Posaconazole: oral solution 200 mg every 8 h; voriconazole oral formulation: 200 mg (3 mg/kg) twice daily</td>
<td>Indicated only in high-risk patients (threshold recommended by experts varies, 8–10% prevalence&lt;sup&gt;[22]&lt;/sup&gt;);&lt;sup&gt;[23]&lt;/sup&gt; to overcome pharmacokinetic limitations associated with the suspension of posaconazole, a new gastro-resistant tablet is advisable&lt;sup&gt;[24]&lt;/sup&gt;.</td>
</tr>
</tbody>
</table>

For references, see supplementary material. BAL=bronchoalveolar lavage. — A randomised, double-blind, comparison of intravenous posaconazole versus voriconazole for invasive pulmonary aspergillosis is underway (NCT02872533). Voriconazole trough concentrations >1 µg/L are more efficacious, but if >4–6 µg/L there is an increased risk of toxicity. In patients with a creatinine clearance <50 mL/min, voriconazole can be administered safely using continuous veno-venous haemofiltration, which selectively removes its potentially toxic vehicle, sulfobutylether-β-cyclodextrin sodium<sup>[25]</sup>. Isavuconazole trough concentrations >1 µg/L are recommended for treatment of mould infection. Isavuconazole levels should be monitored pending further information about pharmacokinetics in real-world patients, although target levels for treatment of mould infection have not been defined. Measurement of trough serum concentrations within the first 5–7 days after initiation of therapy are recommended.<sup>[26]</sup>
search strategy and selection criteria

We searched PubMed for articles on invasive fungal infections in the intensive care setting and in patients with haematological cancer that were published between January, 1996 and December, 2016. We made all efforts to identify papers addressing strategies for risk assessment, fungal diagnosis and antifungal therapy in two different scenarios: intensive care units and patients with haematological cancer. Search terms were not restricted, but included various combinations as follows: “intensive care unit”, “intensive care”, “critically ill patient”, “cancer”, “neutropenia”, “stem cell transplantation”, “candida infection”, “invasive candidiasis”, “candidemia”, “candida bloodstream infection”, “intra-abdominal candidiasis”, “peritoneal candidiasis”, “candida peritonitis”, “aspergillus infection”, “invasive aspergillosis”, “fusarium infection”, “invasive fusariosis”, “zygomycosis”, “mucormycosis”, “scedosporium infection”, “invasive scedosporiosis”, “epidemiology”, “risk factors”, “risk assessment”, “diagnosis”, “prophylaxis”, “treatment”, “diagnostic-driven”, and “empirical therapy”. We reviewed all articles retrieved from these search terms and relevant references cited in those articles. There were no language restrictions.

scanning of the lungs and sinuses, and could safely replace the conventional approach of empirical antifungal therapy for persistent febrile neutropenia.62,102,103

Persistently negative serum galactomannan, 1,3-β-D-glucan, aspergillus PCR, and organ imaging have a high NPV and effectively exclude invasive aspergillosis. Conversely, sequentially positive biomarkers, especially when used in combination, should trigger aggressive diagnostic tests for invasive aspergillosis and initiation of pre-empive antifungal therapy; this has proven effective for earlier diagnosis of invasive aspergillosis in patients who are at high risk.93,102,104 Such an approach is more sensitive than are culture and galactomannan alone, and reduces the use of undirected or empirical antifungal therapy. It should be noted, however, that in patients receiving mould-active prophylaxis and undergoing regular surveillance testing, false positives outnumber true positives because of the associated low pre-test probability.104 Patients receiving mould-active prophylaxis should undergo intensive diagnostic investigations, including imaging, and serum and BAL galactomannan testing, if they develop a new episode of fever or other features suggesting the possibility of fungal infection.102,103,105

Voriconazole, with monitoring of serum levels, remains the treatment of choice for aspergillosis (table 4). Amphotericin B lipid formulation is an alternative. There is no evidence supporting combination antifungal therapy. Isavuconazole was equally effective and less toxic than was voriconazole in a randomised clinical trial, but more real-world experience in populations unbiased by exclusion criteria used in clinical trials is needed.52

Amphotericin B lipid formulation and voriconazole have been recommended for fusariosis treatment (table 4).103 Treatment of mucormycosis is based on: control of underlying disease and predisposing factors (diabetes control, neutropenia, discontinuation or tapering of immunosuppressants, or discontinuation of desferrioxamine mesilate), prompt and aggressive surgical debridement of necrotic tissue, and a lipid formulation of amphotericin B (table 4).103 Most experience has been with liposomal amphotericin B.103 An analysis of 106 cases of mucormycosis in patients with haematological malignancies showed no benefit from combination versus monotherapy.103 Antifungal therapy should be continued until clinical and radiological resolution of disease.103 PET scanning might be useful to monitor response.103 Additional alternatives for antifungal therapy of mucormycosis and treatment recommendations for Scedosporium sp infections are also used (table 4).

Conclusions

Pathogenic Candida spp and moulds cause substantial morbidity and mortality in ICUs and in patients with haematological cancer. Knowledge of incidence and epidemiology, globally and locally, is essential for the selection of appropriate, early antifungal therapy and local adaptation of antifungal guidelines. Understanding new risks and risk prediction algorithms assists with identifying patient categories that benefit most from early intervention strategies. Appreciation of clinical manifestations is also essential. There are increasing data to support use of one or more serological or molecular fungal biomarkers as diagnostic modalities, both for screening and in established IFIs. Standardisation of these tests and improved, validated, diagnostic algorithms are required as a priority. Newer imaging techniques, such as PET, are expected to have an increasing role in diagnostics. Management of IFIs in vulnerable patients includes antifungals, ancillary therapies such as immunomodulation, and surgery where appropriate. Finally, effective liaison between clinicians and diagnostic laboratories is essential to improve antifungal drug use and outcomes.

Contributors

All authors drafted and reviewed the full manuscript. TCS and JNdAJ made major contributions on fungal infections in ICU patients. MAS, SC-AC, and ALC made major contributions on fungal infections in patients with haematological cancer.

Declaration of interests

ALC has received educational grants from Pfizer, Gilead Sciences–United Medical (Brazil), Merck Sharp and Dohme, and a research grant from Astellas. Pfizer. SC-AC has received grants from Merck Sharp and Dohme, sat on advisory boards for Merck Sharp and Dohme and Gilead Sciences, and received travel support and honoraria unrelated to the current work from Merck Sharp and Dohme and Gilead Sciences. MAS has received grants from Merck Sharp and Dohme and Gilead Sciences, sat on advisory boards for Merck Sharp and Dohme and Gilead Sciences, and received travel support and honoraria unrelated to the current work from Merck Sharp and Dohme and Gilead Sciences. The other authors declare no competing interests.
Acknowledgments

TCS is a Sydney Medical School Foundation Fellow. The work of TCS, MAS, and SCAC was supported by the National Health and Medical Research Council of Australia through two Centres of Research Excellence grants (APP1001021 [TCS], APP264605 [TCS, SCAC]) and project grants (APP112307 [TCS, SCAC], APP131105 [TCS, MAS]). ALC has a grant from the National Council of Technological and Scientific Development (CNPQ 307510/2015-8). We would like to thank Jaques Sztajnbok and Amaro N Duarte Neto (Clinics Hospital of São Paulo, São Paulo, Brazil) who kindly provided the photos in the appendix.

References

18 Hollenbach E. To treat or not to treat—critically ill patients with candidemia. Mycoses 2008; 51 (suppl 2): 12–24.


